@RaceOncology - Given RC220 is not ready to be used in the clinic can the Sheba AML trial use RC220 to conclude their AML trial so we can final report although there may not be any significant impact from it? If not, what are the dependencies?
When can we expect research publications in high impact journals? Feels like we have been waiting for some time on this front.
Hopefully we will get some info on the above soon in our quarterly.
@RaceOncology - Given RC220 is not ready to be used in the...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |